Alzheimer's Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Alzheimer's Disease stocks.

Alzheimer's Disease Stocks Recent News

Date Stock Title
May 22 BIIB Sector Update: Health Care Stocks Slightly Higher Late Afternoon
May 22 BIIB Biogen Agrees to Buy Human Immunology Biosciences For up to $1.8 Billion
May 22 BIIB Deep Dive Into Biogen Stock: Analyst Perspectives (17 Ratings)
May 22 BIIB Biogen inks $1.8B deal to acquire immune drug developer HI-Bio
May 22 BIIB Biogen in up to $1.8 billion deal as rare diseases take center stage
May 22 BIIB Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
May 22 BIIB Biogen, looking to diversify, acquires immune drugmaker HI-Bio for $1.15B
May 21 EHAB Enhabit Announces Participation in Upcoming Goldman Sachs 45th Annual Global Healthcare Conference
May 21 IGC IGC Pharma to Attend BIO International Convention 2024
May 21 BIIB Why Biogen Inc. (BIIB) is a Top Momentum Stock for the Long-Term
May 21 CGTX Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
May 20 EHAB Enhabit Announces Participation in Upcoming Leerink Partners Healthcare Crossroads Conference 2024
May 20 BNOX Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
May 18 AXSM 3 Monster Stocks in the Making You Can Buy Right Now
May 17 BIIB Ionis, Biogen Down on Ending Development of ALS Drug
May 17 BIIB Ionis (IONS), Biogen Down on Ending Development of ALS Drug
May 16 BIIB Biogen also drops collaboration with Ionis on Angelman syndrome candidate
May 16 CYTH Cyclo Therapeutics reports Q1 results
May 16 BIIB Biogen and Ionis drop ALS candidate after trial setback
May 16 BIIB Biogen, Ionis shelve ALS drug following study failure
Alzheimer's Disease

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care, and behavioural issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.The cause of Alzheimer's disease is poorly understood. About 70% of the risk is believed to be genetic with many genes usually involved. Other risk factors include a history of head injuries, depression, or hypertension. The disease process is associated with plaques and tangles in the brain. A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal ageing. Examination of brain tissue is needed for a definite diagnosis. Mental and physical exercise, and avoiding obesity may decrease the risk of AD; however, evidence to support these recommendations is not strong. There are no medications or supplements that have been shown to decrease risk.No treatments stop or reverse its progression, though some may temporarily improve symptoms. Affected people increasingly rely on others for assistance, often placing a burden on the caregiver; the pressures can include social, psychological, physical, and economic elements. Exercise programmes may be beneficial with respect to activities of daily living and can potentially improve outcomes. Behavioural problems or psychosis due to dementia are often treated with antipsychotics, but this is not usually recommended, as there is little benefit with an increased risk of early death.In 2015, there were approximately 29.8 million people worldwide with AD. It most often begins in people over 65 years of age, although 4% to 5% of cases are early-onset Alzheimer's which begin before this. It affects about 6% of people 65 years and older. In 2015, dementia resulted in about 1.9 million deaths. It was first described by, and later named after, German psychiatrist and pathologist Alois Alzheimer in 1906. In developed countries, AD is one of the most financially costly diseases.

Browse All Tags